Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „were“
Suchtreffer
Begriffe & Kennungen
Aimovig · 4.8 · In the post-marketing setting, cases of anaphylaxis and angiodoema were observed.
Eintrag öffnenAimovig · 4.8 · The reported adverse drug reactions for 70 mg and 140 mg were injection site reactions (5.6%/4.5%), constipati
Eintrag öffnenAjovy · 4.8 · Commonly reported adverse drug reactions (ADRs) were local reactions at the injection site (pain [24%], indura
Eintrag öffnenAjovy · 4.8 · Injection site reactions The most frequently observed local reactions at the injection site were pain, indurat
Eintrag öffnenAkantior · 4.8 · The adverse reactions listed below were observed in clinical trials in patients treated with AKANTIOR with a r
Eintrag öffnenAkeega · 4.8 · In the MAGNITUDE and AMPLITUDE studies, the following haematological parameters were inclusion criteria: absol
Eintrag öffnenAkynzeo · 4.8 · Common adverse reactions reported with Akynzeo were headache (3.6%), constipation (3.0%) and fatigue (1.2%). N
Eintrag öffnenAkynzeo · 4.8 · Common adverse reactions reported with Akynzeo were headache (3.6%), constipation (3.0%) and fatigue (1.2%). N
Eintrag öffnenAkynzeo · 4.8 · Common adverse reactions reported with netupitant/palonosetron capsules were headache (3.6%), constipation (3.
Eintrag öffnenAkynzeo · 4.8 · Common adverse reactions reported with netupitant/palonosetron sachets were headache (3.6%), constipation (3.0
Eintrag öffnenAldara · 4.8 · Investigators of placebo controlled trials were required to evaluate protocol mandated clinical signs (skin re
Eintrag öffnenAldara · 4.8 · Investigators of the placebo controlled clinical trials were required to evaluate protocol mandated clinical s
Eintrag öffnenAldara · 4.8 · Remote site skin reactions, mainly erythema (44%), were also reported in the placebo controlled trials. These
Eintrag öffnenAldurazyme · 4.8 · In the Phase 2 and 3 studies, 60 patients were tested for in-vitro neutralising effects. Four patients (three
Eintrag öffnenAldurazyme · 4.8 · Summary of the safety profile The majority of the related adverse events in the clinical trials were classifie
Eintrag öffnenAlecensa · 4.8 · Adverse reactions of bilirubin elevations were reported in 25.9 % of the patients treated with Alecensa across
Eintrag öffnenAlhemo · 4.5 · In vitro and ex vivo drug-drug interaction studies were performed with rFVIIa, aPCC, rFVIII or rFIX in blood f
Eintrag öffnenAlhemo · 4.8 · 78 of the clinical trial participants were adolescents (≥ 12 to < 18 years). The safety profile was similar be
Eintrag öffnenAlhemo · 4.8 · Injection site reactions Injection site reactions were reported across the multiple dose clinical trials. The
Eintrag öffnenAloxi · 4.8 · 18 In the clinical studies the following adverse reactions (ARs) were observed as possibly or probably related
Eintrag öffnen